Teeft.i
Analysis
France
Racine
Analysis
France
Exploration
Accueil
Racine
Racine

Serveur d'exploration Tocilizumab - Analysis (France)

Index « Teeft.i » - entrée « Disease duration »
Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.
Disease chronicity < Disease duration < Disease duration years  Facettes :

List of bibliographic references

Number of relevant bibliographic references: 18.
Ident.Authors (with country if any)Title
000514 (2013) Muriel Elhai [France] ; Marine Meunier [France] ; Marco Matucci-Cerinic [Italie] ; Britta Maurer [Suisse] ; Gabriela Riemekasten [Allemagne] ; Tifenn Leturcq [France] ; Raffaele Pellerito [Italie] ; Carlos Alberto Von Mühlen [Brésil] ; Alessandra Vacca [Italie] ; Paolo Airo [Italie] ; Francesca Bartoli [Italie] ; Ginevra Fiori [Italie] ; Maria Bokarewa [Suède] ; Valeria Riccieri [Italie] ; Mike Becker [Allemagne] ; Jérôme Avouac [France] ; Ulf Müller-Ladner [Allemagne] ; Oliver Distler [Suisse] ; Yannick Allanore [France]Outcomes of patients with systemic sclerosis-associated polyarthritis and myopathy treated with tocilizumab or abatacept: a EUSTAR observational study
000528 (2013) A. Meyer [France] ; A. Theulin ; E. Chatelus ; C. Sordet ; R.-M. Javier ; B. Geny [France] ; J.-E. Gottenberg ; J. SibiliaTHU0412 Reactive hyperemia index (RHI) is associated with macrovascular disease and lung disease in systemic sclerosis
000529 (2013) S. Ozen ; E. Demirkaya [Turquie] ; G. Amaryan [Arménie] ; I. Koné-Paut [France] ; P. Woo [Royaume-Uni] ; Y. Uziel [Israël] ; M. Finetti [Italie] ; P. Quartier [France] ; C. Modesto [Espagne] ; E. Papadopoulou-Alataki [Grèce] ; S. Nielsen [Danemark] ; M. Hofer [Suisse] ; A. Polat [Turquie] ; T. Turker [Turquie] ; A. Insalaco [Italie] ; L. Cantarini [Italie] ; S. M. Al-Mayouf [Arabie saoudite] ; J. Frenkel [Pays-Bas] ; H. Ozdogan [Turquie] ; N. Ruperto [Italie] ; M. Gattorno [Italie]THU0334 Differences in the features of familial mediterranean fever among patients from europe as compared to those from the eastern mediterranean countries
000532 (2013) I. Castrej N [États-Unis] ; M. Dougados [France] ; B. Combe [France] ; F. Guillemin [France] ; B. Fautrel [France] ; T. Pincus [États-Unis]THU0165 Predictive Value of Different Remission Criteria for a Good Functional Status Outcome: Results from the Espoir Cohort
000533 (2013) C. Gaujoux-Viala [France] ; L. Gossec [France] ; M. Dougados [France] ; F. Guillemin [France] ; B. Fautrel [France]THU0134 Favorable Outcome, a New Concept for the Evaluation of Health Status in Rheumatoid Arthritis (RA) not so Easy to Achieve: Results from the Espoir Cohort
000534 (2013) Y.-M. Pers [France] ; C. Fortunet ; E. Constant ; J. Lambert [France] ; A. Mazouyes [France] ; M. Valnet [France] ; H. Marotte ; P. Gaudin [France] ; D. Wendling [France] ; J.-F. Maillefert ; C. Jorgensen [France]THU0126 Multicenter retrospective study: Response to tocilizumab in clinical practice is not influenced by the number of previous biotherapy or by association with a DMARD
000538 (2013) L. Gossec [France] ; S. Rouanet ; G. Steinberg ; B. Combe [France]THU0063 Does biologic treatment modify the relationship of the variables associated with fatigue in patients with rheumatoid arthritis? The peps study of tocilizumab in real life
000549 (2013) Alessandra Blaizot [France] ; Paul Monsarrat [France] ; Arnaud Constantin [France] ; Jean-Noel Vergnes [France] ; Gabriel Fernandez De Grado [France] ; Cathy Nabet [France] ; Alain Cantagrel [France] ; Michel Sixou [France]Oral health‐related quality of life among outpatients with rheumatoid arthritis
000553 (2013) A. Ruyssen-Witrand [France] ; P.-A. Gourraud [États-Unis] ; D. Nigon [France] ; C. Lukas [France] ; C. Miceli-Richard ; B. Jamard ; A. Cantagrel ; A. Cambon-Thomsen [France] ; P. Dieudé [France] ; A. Constantin [France]OP0050 Evolution of the alternative classification of HLA-DRB1 alleles in rheumatoid arthritis: Impact on the production of the anti-citrullinated protein antibodies and structural progression, data from the ESPOIR cohort
000557 (2013) K. Sacre [France] ; M. Dehoux [France] ; M. Chauchard [France] ; D. Gobert [France] ; E. Pasqueloni [France] ; C. Compain [France] ; J.-F. Alexandra [France] ; M.-P. Chauveheid [France] ; O. Lidove [France] ; R. Roussel [France] ; T. Papo [France]FRI0546 Pituitary-adrenal function after prolonged glucocorticoid therapy in systemic disorders
000563 (2013) J. Morel [France] ; M. O. Duzanski [France] ; A. Cantagrel [France] ; B. Combe [France] ; M. Dougados [France] ; R. M. Flipo ; J. E. Gottenberg [France] ; X. Mariette [France] ; O. Vittecoq ; A. Saraux ; T. Schaeverbeke ; T. Bardin [France] ; M. Soubrier ; P. Ravaud [France] ; J. Siblia [France]FRI0245 Prospective follow-up of tocilizumab treatment in 1100 patients with refractory rheumatoid arthritis: tolerance data from the french registry regate (registry –roactemra)
000564 (2013) J. S. Smolen [Autriche] ; J. Wollenhaupt [Allemagne] ; P. Durez [Belgique] ; J. Gomez-Reino [Espagne] ; W. Grassi [Italie] ; M. Le Bars [France] ; C. Gaillez [France] ; C. Poncet [France] ; R. Westhovens [Belgique]FRI0242 Time to achieve remission and sustained remission for mtx-naïve patients with early ra treated with abatacept plus mtx versus mtx alone in the agree trial
000568 (2013) A.-P. Trouvin ; S. Jacquot ; S. Grigioni ; H. Boulard ; I. Dutot ; O. Vittecoq ; X. Le Loet ; O. Boyer ; V. Goeb [France]FRI0215 Transitional and memory b cell analysis is an essential tool to anticipate clinical relapse in rheumatoid arthritis (RA) patients treated with rituximab
000569 (2013) P. Emery [Royaume-Uni] ; R. Westhovens [Belgique] ; M. Dougados [France] ; R. Alten [Allemagne] ; C. Gaillez ; C. Poncet [France] ; M. Le Bars ; A. Elegbe ; H. Genant [États-Unis]FRI0199 In patients with established RA, abatacept efficacy is independent of baseline annual radiographic progression rate
000570 (2013) M. Kostine ; T. Barnetche ; E. Ardouin ; M. Joly [France] ; E. Rabois [France] ; B. Glace [France] ; T. Schaeverbeke ; C. RichezFRI0192 Is early neutropenia associated with clinical response in patients receiving tocilizumab in rheumatoid arthritis?
000573 (2013) I. Castrejon [États-Unis] ; T. Pincus [États-Unis] ; M. Soubrier [France] ; Y. C. Lin [États-Unis] ; M. Dougados [France]FRI0077 Relative efficiencies of joint counts and laboratory tests are no higher than patient-reported measures to document superior results in the guepard tight-control versus espoir routine care cohorts
000587 (2013) S. Cadart ; L. Kanagaratnam [France] ; J. Corli ; R.-M. FlipoAB0359 Doctor/patient match in disease evaluation activity in rheumatoid arthritis
000628 (2012) A. Ruyssen-Witrand [France] ; S. Rouanet [France] ; B. Combe [France] ; M. Dougados [France] ; X. Le Loët [France] ; J. Sibilia [France] ; J. Tebib [France] ; X. Mariette [France] ; A. Constantin [France]Fcγ receptor type IIIA polymorphism influences treatment outcomes in patients with rheumatoid arthritis treated with rituximab

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/TocilizumabV1/Data/France/Analysis

HfdIndexSelect -h $EXPLOR_AREA/Data/France/Analysis/Teeft.i -k "Disease duration" 

HfdIndexSelect -h $EXPLOR_AREA/Data/France/Analysis/Teeft.i  \
                -Sk "Disease duration" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/France/Analysis/biblio.hfd

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    TocilizumabV1
   |flux=    France
   |étape=   Analysis
   |type=    indexItem
   |index=    Teeft.i
   |clé=    Disease duration
}}
Wicri

This area was generated with Dilib version V0.6.34.
Data generation: Fri May 22 09:34:00 2020. Site generation: Sun Mar 28 09:01:19 2021